csirt@kutim:~/threat-intel/cve/CVE-2023-25149

Katalog CVE

CVSS 8.8 · High EPSS 0,78%

Kerentanan Improper Access Control pada timescaledb. Skor CVSS 3.1 8.8 (High) menurut NVD.

Deskripsi (NVD)

TimescaleDB, an open-source time-series SQL database, has a privilege escalation vulnerability in versions 2.8.0 through 2.9.2. During installation, TimescaleDB creates a telemetry job that is runs as the installation user. The queries run as part of the telemetry data collection were not run with a locked down `search_path`, allowing malicious users to create functions that would be executed by the telemetry job, leading to privilege escalation. In order to be able to take advantage of this vulnerability, a user would need to be able to create objects in a database and then get a superuser to install TimescaleDB into their database. When TimescaleDB is installed as trusted extension, non-superusers can install the extension without help from a superuser. Version 2.9.3 fixes this issue. As a mitigation, the `search_path` of the user running the telemetry job can be locked down to not include schemas writable by other users. The vulnerability is not exploitable on instances in Timescale Cloud and Managed Service for TimescaleDB due to additional security provisions in place on those platforms.

Rincian

Terbit di NVD
14 Februari 2023
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
8.8 (High), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-284: Improper Access Control
CWE-269: Improper Privilege Management
EPSS (30 hari)
0,78% peluang dieksploitasi; lebih tinggi dari 54,5% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
timescale timescaledb Versi 2.8.0 hingga 2.9.2

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.